The stock market has performed remarkably well lately. Within the last 12 months, the S&P 500, a benchmark representation of the U.S. stock market comprised of the 500 largest publicly traded companies, has increased by 26%. To put that into perspective, the average return for the S&P 500 annually since its inception is approximately 10%. Thus, it has nearly tripled the average rate of return recently due to evident positive sentiment from investors. A reduction in inflation with rate cuts on the horizon, i ...

Ardelyx Inc (NASDAQ:ARDX) stock was last seen 0.6% lower at $7.75, extending a pullback from its Feb. 12, nearly seven-year high of $10.13. The shares are down 16.3% so far this month and underperforming a 3% March gain for the broader market SPDR S&P 500 ETF Trust (SPY). However, this deficit may present the perfect buying opportunity if history is any indicator.ARDX just pulled back to a historically bullish trendline on the charts. According to data from Schaeffer's Senior Quantitative Analyst Rocky Whit ...

Finding the next great investment is alluring, almost like a siren’s song. For this, one must possess a crystal ball to identify the stocks about to soar, elevating portfolios to unprecedented heights. Ok, let’s set aside the crystal ball. Let’s dive into three titans in their own fields with stories full of potential and promise.To begin with, there is a ground-breaking therapy for irritable bowel syndrome that derives the first one’s rapid climb. And then there’s the second one, the behemoth of Latin Amer ...

Koh Sze Kiat/E+ via Getty ImagesOn January 8, Ardelyx (NASDAQ:ARDX) provided a surprise business update. The stock surged that day to $8.18 (+33%) after management proclaimed that lead product IBSRELA (tenapanor for irritable bowel syndrome with constipation [IBS-C]) would corner 10% market share on its way to blockbuster status on US net product sales alone. Originally scheduled for February 29, the Q4 2023 financial report was bumped up to February 22, normally a good sign, but my previous coverage wa ...

In the stock market, identifying potential millionaire-making stocks can lead to a situation like finding needles in a haystack. However, under ongoing volatility, three companies have emerged as prime contenders for high returns. Beyond names, these companies hold a strategic edge, rapid growth capabilities, and solid market strategies.The first one stands at the edge of AI-based solutions, leveraging strategic partnerships and an operational edge to propel its valuation. Meanwhile, the second one defies m ...

Start Time: 16:30 January 1, 0000 5:21 PM ET Ardelyx, Inc. (NASDAQ:ARDX) Q4 2023 Earnings Conference Call February 22, 2024, 16:30 PM ET Company Participants Mike Raab - President and CEO Justin Renz - Chief Financial and Operations Officer Laura Williams - CMO Susan Rodriguez - Chief Commercial Officer Caitlin Lowie - VP of Corporate Communications and IR Conference Call Participants Dennis Ding - Jefferies Chris Raymond - Piper Sandler Laura Chico - Wedbush Louise Chen - Cantor Fitzgerald Yigal Nochomovit ...

Ardelyx (ARDX) reported $34.36 million in revenue for the quarter ended December 2023, representing a year-over-year decline of 22.2%. EPS of -$0.12 for the same period compares to $0.06 a year ago.The reported revenue represents a surprise of -0.18% over the Zacks Consensus Estimate of $34.42 million. With the consensus EPS estimate being -$0.09, the EPS surprise was -33.33%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Stre ...

Ardelyx (ARDX) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to earnings of $0.06 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -33.33%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.11 per share when it actually produced earnings of $0.03, delivering a surprise of 127.27%.Over the last four quarters, the compan ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ____________________________________________________ FORM 10-K ____________________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36485 ___ ...

Investing in high-potential biotech stocks should catapult your portfolio to new heights. Picture this: a global biotech market valued at a whopping $1.55 trillion in 2023 is set to catapult to $3.08 trillion by 2030, with a compound annual growth rate of 14%. Beyond the numbers, the competitive fervor among biotechs adds an intriguing layer to this dynamic sector. In the face of such exponential growth, savvy investors have a unique opportunity to ride the wave of innovation and financial prosperity ahead. ...